MGM

MGM Bio is an early-stage biotechnology company based in Copenhagen, Denmark, focused on discovering novel antiviral small molecules. The company uses a metagenomics-based discovery approach to access bioactive molecules from soil microbes that are difficult to reach through conventional screening methods. Its positioning appears to be business-to-business, with an emphasis on supplying novel antiviral leads to the pharmaceutical industry rather than marketing approved products directly. Publicly available information suggests the company is platform-oriented and remains at a very early development stage, with no disclosed clinical-stage assets.